Last reviewed · How we verify
Ibrutinib (Induction)
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells. Used for Chronic lymphocytic leukemia (CLL), induction phase, Mantle cell lymphoma, induction phase, Waldenström macroglobulinemia, induction phase.
At a glance
| Generic name | Ibrutinib (Induction) |
|---|---|
| Also known as | Imbruvica |
| Sponsor | Prof. Dr. M. Dreyling (co-chairman) |
| Drug class | Bruton's tyrosine kinase (BTK) inhibitor |
| Target | BTK (Bruton's tyrosine kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ibrutinib covalently binds to BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, it disrupts downstream signaling cascades that promote B-cell survival and proliferation, making it particularly effective against B-cell malignancies. In the induction phase, it is used as an initial treatment to rapidly reduce tumor burden before consolidation or maintenance therapy.
Approved indications
- Chronic lymphocytic leukemia (CLL), induction phase
- Mantle cell lymphoma, induction phase
- Waldenström macroglobulinemia, induction phase
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Bruising/bleeding
- Infection
- Atrial fibrillation
- Neutropenia
Key clinical trials
- MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (PHASE2)
- Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance (PHASE2)
- Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (PHASE2)
- Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia (PHASE2)
- LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (PHASE1, PHASE2)
- National Project on Vaccines, COVID-19 and Frail Patients
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia (PHASE2)
- Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibrutinib (Induction) CI brief — competitive landscape report
- Ibrutinib (Induction) updates RSS · CI watch RSS
- Prof. Dr. M. Dreyling (co-chairman) portfolio CI